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Abstract 
This observational study reports the long-term follow-up of 184 Parkinson’s disease (PD) patients 
treated with subthalamic deep brain stimulation (STN-DBS), retrospectively analyzing the outcomes 
of subjects with pre-surgical mild cognitive impairment (MCI) compared to those of patients with 
normal cognition. Patients were divided into PD-MCI or normal cognition groups at baseline, and 
then compared after 1, 3, 5 and >5 years of follow-up. Subjects assessed by outpatient clinical 
follow-up evaluation, not performing a complete clinical and neuropsychological follow-up 
assessment, were separately considered and rated according to their functional autonomy in daily 
living activities. The MCI prevalence at baseline was 23 %, increasing to 34 % at 1 year and over 
40 % after 3 years. Dementia progressively affected more than 30 % of subjects after a median time 
of 6 years in the PD-MCI group and 11 years in the normal cognition group (p: 0.028). The 
mortality risk was slightly higher in PD-MCI patients. Outpatient clinical evaluations showed a 
progressive increase of subjects completely dependent in the activities of daily living, which ranged 
from the 11 % at 3 years to 23 % at 5 years and 31 % at >5 years. MCI can be frequently observed 
in PD patients, possibly influencing the outcome of surgical therapy. Our findings confirm the 
sustained long-lasting efficacy of STN-DBS on motor functions in both PD-MCI and normal 
cognition subjects. PD-MCI patients showed a more precocious cognitive impairment, as expected 
by natural history studies, but no case of dementia was observed early after surgery. 
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Introduction 
 Mild cognitive impairment (MCI) can be observed since the onset of Parkinson’s disease 
(PD) [1, 3], representing the initial phase of PD cognitive impairment and an important risk factor for 
the development of Parkinson’s-associated dementia (PD-D) [4]. 
 As suggested by the recent formulation of specific Movement Disorder Society (MDS) 
criteria for PD-MCI, an early identification of PD cognitive deficits could be particularly relevant 
for the long-term prognosis of PD; this could be especially relevant in patients’ candidates to 
surgical therapies such as subthalamic nucleus deep brain stimulation (STN-DBS). In fact, long-
term follow-up studies on STN-DBS treated patients [5, 7] demonstrated that stimulation efficacy 
could be limited by the progressive development of neuropsychological alterations, even though 
few data have been reported on the long-term STN-DBS outcomes in relation to the baseline 
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cognitive performances. The majority of follow-up studies focused only on patients reaching the 
long-term evaluation, without considering subjects who developed dementia or died after a variable 
period of time after DBS. 
 In a recent review on DBS for PD, facing the issue of patient selection, Bronstein et al.[8] 
reported that best results could be observed in patients with advanced PD and excellent L-Dopa 
response, younger age, no or few axial non-L-Dopa-responsive motor symptoms, no or very mild 
cognitive impairment. However, no data have been reported yet about the presence of the PD-MCI 
in predicting the long-term outcomes of STN-DBS subjects. 
 This study analyzes the role of PD-MCI in patients treated with STN-DBS. We 
retrospectively divided 184 patients into PD-MCI and normal cognition groups, following the 
criteria suggested by Litvan et al. [1], with the aim of evaluating whether the pre-surgical PD-MCI 
feature may influence the long-term cognitive and motor outcomes. 
 
Methods 
 All 184 PD patients treated with STN-DBS at our Centre between 1998 and 2010 were 
included in the study. Subjects were selected according to the Core Assessment Program for 
Surgical Interventional Therapies in Parkinson’s disease (CAPSIT-PD)[9] and STN-DBS bilateral 
surgery was performed following the procedure previously described elsewhere[10]. 
 A complete Unified Parkinson’s disease Rating Scale (UPDRS) examination was performed 
at baseline (before STN-DBS), both in “OFF-condition” (at least 12 h after the last levodopa dose) 
and in “ON-condition” (at least 40 min after a levodopa challenge dose, consisting in 1.5 times the 
usual morning dose). In addition, the UPDRS-III axial subscore was calculated by the sum of items 
18 (speech), 22 (neck rigidity), 27 (arising from a chair), 28 (posture), 29 (gait) and 30 (postural 
stability). A periodical clinical and neuropsychological CAPSIT-PD assessment, performed during 
a brief hospitalization, was proposed to each subject at 1, 3, 5 and >5 years (or more frequently 
according to the medical needs) in four conditions: Stimulation ON/Medication OFF; Stimulation 
OFF/Medication OFF; Stimulation OFF/Medication ON; Stimulation ON/Medication ON. Some 
patients underwent clinical outpatient evaluations only, basing on their familial needs or logistical 
problems. These subjects were then classified as completely independent, partially dependent or 
completely dependent in the ADL, taking into account the patients’ autonomy in bathing, dressing, 
toileting, transferring, feeding and continence[11] in relation to the cognitive status and to the 
parkinsonian motor symptoms. 
 All PD patients were evaluated with a standardized battery of cognitive tests previously 
described [12]. Visuo-spatial reasoning was evaluated by means of the Raven Colour Matrices (PM 
47)[13]; verbal and spatial short-term memory were assessed by means of the validated versions of 
the Italian Bi-syllabic Words Repetition test (BWR) and Corsi’s Block Tapping test (CBT)[14]. The 
assessment of verbal learning was achieved by means of the Paired Associate Learning (PAL)[15], a 
Wechsler Memory Scale subtest. Frontal lobe executive functions, including the development of 
abstract concepts and the shift of attentional and motor sets, were assessed by means of the Trail 
Making B[16]. In addition, patients were administered the Phonemic and Category Verbal Fluency 
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tasks[14, 17]. Age and education appropriate normative data were used to evaluate the 
neuropsychological tests. In order to obtain comparable categorical data each test was rated as: 
normal performances, limited performances, moderate impairment, severe impairment, according to 
the scoring reported by Aybeck et al.[18]. Depression was evaluated by means of the Beck 
Depression Inventory (BDI), a 21-item self-rated scale[19]. The activities of daily living (ADL) 
functional impairment due to neuropsychological deficits were evaluated by means of a clinical 
diagnostic interview, administered to patients and caregivers by a trained neuropsychologist at each 
neuropsychological evaluation, taking into account the UPDRS-II score in “ON-condition”. PD-
MCI was retrospectively defined as moderate or severe impairment on at least two 
neuropsychological tests and cognitive deficits not sufficient to interfere significantly with 
functional independence, in accordance with the Level-I of MDS criteria[20]. PD-D was defined 
according to the MDS criteria[21] as impairment in more than one cognitive domain with a decline 
from premorbid level and deficits severe enough to impair daily life, independently from the 
impairment ascribable to motor or autonomic symptoms. Table 1 reports a complete list of clinical 
and demographic variables at baseline, including the number of patients fulfilling the criteria for 
PD-MCI (23 %) and normal cognition (77 %); in case of pre-surgical missing data (10 subjects), 
patients were excluded from the analysis. The study was approved by the local ethical committee, 
and a written informed consent was signed by all patients included.  
Table 1: Demographic and clinical data at the pre-surgical baseline evaluation. 
 
Column ‘‘p’’ reports the ‘‘p value’’ of the differences between ‘‘normal cognition’’ and ‘‘PD-MCI’’ patients. 
* Significant difference (p\0.05). 
 
Statistical analysis 
 Descriptive statistics (mean, SD and range) were used for continuous variables, while 
categorical variables were described as percentages of subjects falling in each group. The median 
Total  Normal cognition  MCI  p  
Baseline evaluation      
Number of patients  174  134 (77 %)  40 (23 %)   
Gender (M/F)  104/70 (59.8 %/40.2 %)  78/56 (58.2 %/41.8 %)  27/13 (67.5 %/32.5 %)  0.390 
Age at onset (years)  46.40 ± 7.30 (24–59)  46.39 ± 7.01 (24–59)  45.53 ± 7.72 (26–57)  0.765 
Age at DBS (years)  60.31 ± 6.72 (37–70)  60.32 ± 6.12 (40–70)  59.74 ± 8.21 (37–70)  0.856 
Disease duration (years)  13.91 ± 4.75 (7–28)  13.93 ± 4.78 (7–28)  14.21 ± 4.90 (6–25)  0.207 
Motor fluctuation duration  5.86 ± 3.92 (1–23)  5.85 ± 4.04 (1–23)  6.29 ± 3.57 (1–19)  0.207 
(years)      
LEDD (mg/day)  1,063.59 ± 409.73  1,061.94 ± 357.04  1,118.78 ± 459.87  0.706 
 (100–2,435)  (100–2,300)  (325–2,435)   
UPDRS I  1.64 ± 1.48  1.68 ± 1.47  1.58 ± 1.47  0.641 
UPDRS II OFF  22.73 ± 7.27  21.83 ± 7.11  24.78 ± 7.74  0.005* 
UPDRS II ON  7.68 ± 5.38  7.18 ± 5.55  9.30 ± 5.28  0.013* 
UPDRS III OFF  47.51 ± 15.61  46.40 ± 15.43  53.07 ± 12.88  0.005* 
UPDRS III ON  16.91 ± 8.23  15.76 ± 7.84  20.27 ± 8.07  0.001* 
UPDRS III OFF axial subscore  20.60 ± 7.02  19.70 ± 6.93 23.30 ± 6.63  0.014* 
UPDRS III ON axial subscore  8.57 ± 4.17  7.95 ± 4.02  10.45 ± 4.07  0.001* 
UPDRS IV  7.97 ± 3.64  7.89 ± 3.65  8.50 ± 3.42  0.419 
UPDRS V OFF  3.46 ± 0.99  3.29 ± 0.99  3.89 ± 0.83  0.001* 
UPDRS V ON  2.62 ± 0.81  2.05 ± 0.79  2.31 ± 0.62  0.047* 
UPDRS VI OFF  0.49 ± 0.20  0.50 ± 0.23  0.39 ± 0.19  0.003* 
UPDRS VI ON  0.87 ± 0.14  0.84 ± 0.22  0.83 ± 0.23  0.601 

















































































































































































































Baseline demographic and clinical characteristics. 
 The criteria for PD-MCI were fulfilled by 23 % of patients at baseline (Table 1), while no 
subject was affected by dementia. PD-MCI patients showed higher scores of UPDRS-II, -III, -V, 
axial subscores (both in OFF and ON condition) and lower scores of UPDRS-VI in OFF condition 
(Table 1). Gender, age at the disease onset, age at surgery and levodopa equivalent daily dose 
(LEDD) were similar in PD-MCI and normal cognition patients. 
Follow-up evaluations: PD-D and PD-MCI rates and estimated time to dementia development. 
As shown in Fig. 1, no case of PD-D was observed at the first follow-up, while 14 % of subjects 
developed PD-D at 3 years and this percentage rose to 32 % at >5 years.  
 The effects of STN-DBS surgery on PD-MCI and normal cognition group were compared for 
each neuropsychological test between baseline and 1 year after surgery, observing no significant 
changes for the majority of tests. The only exception was represented by the Phonemic Verbal 
Fluency, which showed a more marked decrease in the group of normal cognition patients (Table 
2). 
Table 2 Neuropsychological assessment in PD-MCI and normal cognition groups: baseline versus 1-year follow-up 
scores. 
Baseline  1 year  p  
Raven Colour Matrices––PM47    
Normal 28.12 ± 4.108  28.33 ± 3.766  0.441  
MCI 25.98 ± 5.276  25.32 ± 4.956   
Bi-syllabic Words Rep. test––BWT    
Normal 4.47 ± 0.789  4.22 ± 0.772  0.932  
MCI 3.98 ± 0.740  3.84 ± 0.602   
Corsi’s Block Tapping test––CBT    
Normal 4.43 ± 0.797  4.29 ± 0.852  0.995  
MCI 4.14 ± 0.774  4.00 ± 0.913   
Paired Associate Learning––PAL    
Normal 11.98 ± 2.932  11.31 ± 2.925  0.140  
MCI 10.29 ± 3.372  10.57 ± 3.060   
Trail Making B––TMB    
Normal 182.35 ± 118.379  207.84 ± 138.369  0.993  
MCI 290.54 ± 168.652  306.33 ± 184.837   
Phonemic Verbal Fluency    
Normal 43.30 ± 15.422  33.12 ± 13.449  0.002*  
MCI 30.69 ± 12.330  30.41 ± 13.991   
Category Verbal Fluency    
Normal 21.03 ± 5.572  18.85 ± 8.401  0.345  
MCI 16.78 ± 4.868  16.02 ± 3.941   
Column ‘‘p’’ reports the ‘‘p value’’ of the differences between ‘‘normal cognition’’ and ‘‘PD-MCI’’ patients 
* Significant difference (p\0.05). 
 After the first year, 34 % of subjects were classified as PD-MCI and this percentage rose to 
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trend was observed in the percentage of outpatient subjects requiring assistance in the ADL, partly 
due to the cognitive status and partly to the parkinsonian motor symptoms. 
 The estimated time to PD-D conversion was 11 years for the normal cognition group and 6 
years for the PD-MCI group. These findings might resemble those described by the natural history 
PD studies[22, 25, 26], although only few data are currently available on the long-term follow-up of PD-
MCI patients: Janvin et al.[25] described a PD-MCI conversion rate to PD-D of 62 % in a 4-year 
follow-up study, while Broeders et al.[22] reported a 26 % conversion rate to PD-D over a 5-year 
follow-up, in a cohort of naïve patients. Nevertheless, no reliable comparison can be made with the 
general PD population, since STN-DBS patients represent a highly selected cohort of PD subjects. 
Mortality rate showed a similar trend, rising to 25 % in PD-MCI patients compared to 12 % in the 
normal cognition group, possibly indicating a different incidence of severe complications or a 
different disease progression between the two groups. 
 Taken together, these data seem to suggest that STN-DBS surgery has beneficial effects both 
in PD-MCI and in normal cognition patients with a different incidence of PD-D. Moreover, we 
observed that our cohort of PD-MCI patients had higher baseline score of UPDRS-II and -III and 
lower UPDRS-VI scores; it is questionable whether a more precocious surgical approach should 
have been proposed, to provide a longer symptomatic STN-DBS beneficial effect and prevent the 
development of severe motor complications[27]. 
 Contrasting neuropsychological data have been reported on PD patients treated with STN-
DBS: some studies suggested that cognitive outcomes might follow the natural history of the 
disease[5, 28], whereas others reported an increased risk of dementia early after surgery[29, 30]. 
 At the present time, no clear indications exist for the STN-DBS selection in MCI patients, 
although this condition is very frequent in PD subjects candidates to surgery[26, 31]. 
 In conclusion, our study seems to confirm the safety and beneficial effects of STN-DBS 
surgery on motor functions also in PD-MCI patients with some predictable differences in the long-
term cognitive outcomes. The main study strength is represented by the comprehensive analysis of 
short- and long-term follow-up outcomes of an entire cohort of STN-DBS subjects, while the 
principal limitations are: (a) the neuropshycological battery used, which was chosen before 1998, 
when there was no general consensus on the type of testing to establish cognitive impairment in PD 
subjects[8], (b) the partial data collected in patients with outpatient clinical evaluations and (c) the 
retrospective analysis of data, which require confirmation by further prospective longitudinal 
studies. 
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